Fill out the form to download your copy and see the results.

Evaluating an Artificial Intelligence (AI) Platform to Monitor and Increase Medication Adherence in CNS Trials

 

In this poster you will learn: 

  • Nonadherence in CNS studies ranges from 13% to 39% and contributes to the high failure rate of Phase II and Phase III trials. Traditional monitoring methods such as pill counts and self-reports are imprecise, incomplete, and underestimate nonadherence.
  • Poor adherence can impact final analyses in four ways, by: Reducing the signal-to-noise ratio, diminishing our ability to detect an effect, increasing costs, and incorrect no-go decisions.